TrialJournal for immunotherapy of cancer2022

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.

Nikhil I Khushalani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.